You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 25, 2026

Details for New Drug Application (NDA): 021908

✉ Email this page to a colleague

NDA 021908 describes AMITIZA, which is a drug marketed by Sucampo Pharma Llc and is included in one NDA. It is available from twelve suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the AMITIZA profile page.

The generic ingredient in AMITIZA is lubiprostone. There are ten drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the lubiprostone profile page.

Summary for 021908

Tradename:	AMITIZA
Applicant:	Sucampo Pharma Llc
Ingredient:	lubiprostone
Patents:	3

Pharmacology for NDA: 021908

Mechanism of Action	Chloride Channel Activators

Medical Subject Heading (MeSH) Categories for 021908

Chloride Channel Agonists

Suppliers and Packaging for NDA: 021908

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
AMITIZA	lubiprostone	CAPSULE;ORAL	021908	NDA AUTHORIZED GENERIC	Par Health USA, LLC	0254-3028	0254-3028-02	60 CAPSULE, GELATIN COATED in 1 BOTTLE (0254-3028-02)
AMITIZA	lubiprostone	CAPSULE;ORAL	021908	NDA AUTHORIZED GENERIC	Par Health USA, LLC	0254-3029	0254-3029-02	60 CAPSULE, GELATIN COATED in 1 BOTTLE (0254-3029-02)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	24MCG
Approval Date:	Jan 31, 2006	TE:	AB	RLD:	Yes
Patent:	8,026,393	Patent Expiration:	Oct 25, 2027	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	8,338,639	Patent Expiration:	Jan 23, 2027	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	8,779,187	Patent Expiration:	Jan 23, 2027	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 021908

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-001	Jan 31, 2006	7,064,148	⤷ Start Trial
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-001	Jan 31, 2006	8,114,890	⤷ Start Trial
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-002	Apr 29, 2008	8,748,481	⤷ Start Trial
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-002	Apr 29, 2008	5,284,858	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.